J Korean Neurol Assoc.
2013 Feb;31(1):26-31.
Clinical and Pathological Features of Clevudine Induced Myopathy
- Affiliations
-
- 1Department of Neurology, Catholic University of Daegu School of Medicine, Daegu, Korea.
- 2Department of Neurology, Pusan National University School of Medicine, Busan, Korea. dskim@pusan.ac.kr
- 3Department of Neurology, Yeungnam University College of Medicine, Daegu, Korea.
- 4Department of Neurology, Chonnam National University School of Medicine, Gwangju, Korea.
- 5Department of Neurology, Kyungpook National University School of Medicine, Daegu, Korea.
- 6Department of Neurology, University of Ulsan College of Medicine, Seoul, Korea.
- 7Department of Neurology, Gyeongsang National University School of Medicine, Jinju, Korea.
- 8Department of Pathology, Pusan National University School of Medicine, Busan, Korea.
Abstract
- BACKGROUND
Clevudine (Revovir(R)) is a recently introduced antiviral drug, and clinical trials have demonstrated its potent, sustained antiviral activity without specific adverse events. However, several studies have found severe myopathy during clevudine therapy. Our study aimed to summarize the clinical and pathological features of clevudine-induced myopathy.
METHODS
We analyzed the demographic data, clinical features, and pathologic findings of 18 consecutive hepatitis-B patients who developed skeletal myopathy during clevudine therapy.
RESULTS
The 18 patients comprised 11 women and 7 men aged 48.2+/-14.0 years (mean+/-standard deviation; range 28-74 years). Each of the 18 patients was treated with clevudine for at least 5 months (range 5-20 months) before the development of symptoms. In all patients the main symptom was proximal muscular weakness that progressed slowly over several months. Elevated creatine kinase and myopathic patterns on electromyography were found. Muscle biopsies revealed severe myonecrosis associated with numerous ragged red fibers and cytochrome-c-oxidase-negative fibers, mitochondrial proliferation, and predominant type-II fiber atrophy. The muscle weakness gradually improved within 20 weeks after discontinuation of clevudine.
CONCLUSIONS
Clevudine therapy can induce myopathy associated with mitochondrial toxicity. Careful clinical and laboratory monitoring of the skeletal muscle dysfunction is required in patients receiving clevudine therapy.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Clevudine Induced Mitochondrial Myopathy
- Efficacy of Entecavir Switching Therapy in Chronic Hepatitis B Patients with Clevudine-induced Myopathy
- Clevudine therapy in patients with chronic hepatitis B
- Clinical and Virological Responses to Clevudine Therapy of Hepatocelluar Carcinoma Patients with Chronic Hepatitis B
- Myopathy due to Chronic Clevudine Therapy: A Case Report
